FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016040578> ?p ?o ?g. }

• W2016040578 endingPage "828" @default.
• W2016040578 startingPage "827" @default.
• W2016040578 abstract "To the Editor: We read with interest the letter by Dr Reuser titled “Inconsistent Reporting About Dosing, Dosing Regimen, and Immunomodulation Therapy in Pompe Disease.”1.Reuser AJJ. Inconsistent reporting about dosing, dosing regimen, and immunomodulation therapy in Pompe disease. Genet Med 2012; doi:10.1038/gim.2012.80.Google Scholar In our 2001 article, “Recombinant Human Acid α-Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of a Phase I/II Clinical Trial,”2.Amalfitano A. Bengur A.R. Morse R.P. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.1:CAS:528:DC%2BD3MXislagu7g%3D1128622911286229Genet Med. 2001; 3: 132-138Google Scholar we had reported the initial use of recombinant human acid α-glucosidase (rhGAA) in three infantile patients with Pompe disease.This was a clinical study where important conclusions were drawn. At that time, we had hypothesized that the lack of sustained efficacy of rhGAA in terms of muscle strength in patients 1 and 2 after 3 to 4 months of the initiation of the therapy was likely due to onset of antibodies against rhGAA in these cross-reactive immunologic material–negative patients, in contrast to the lack of an antibody response noted in the cross-reactive immunologic material–positive patient 3.As several subsequent trials have borne out, the observations and conclusions drawn have been repeated and confirmed, both in regard to the impact that cross-reactive immunologic material–positive status with low antibody titers has on potential for significant cardiac improvement and improvement in motor strength.3.Nicolino M. Byrne B. Wraith J.E. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.1:CAS:528:DC%2BD1MXjt1Sruro%3D10.1097/GIM.0b013e31819d0996Genet Med. 2009; 11: 210-219Google Scholar,4.Kishnani P.S. Corzo D. Nicolino M. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.1:CAS:528:DC%2BD2sXosFSg10.1212/01.wnl.0000251268.41188.04Neurology. 2007; 68: 99-109Google Scholar,5.Kishnani P.S. Goldenberg P.C. DeArmey S.L. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.1:CAS:528:DC%2BD1MXhsFGgtb7I10.1016/j.ymgme.2009.08.003Mol Genet Metab. 2010; 99: 26-33Google Scholar,6.Banugaria S.G. Prater S.N. Ng Y.K. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.1:CAS:528:DC%2BC3MXpvVCjurk%3D10.1097/GIM.0b013e3182174703Genet Med. 2011; 13: 729-736Google Scholar,7.Kishnani P.S. Corzo D. Leslie N.D. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.1:CAS:528:DC%2BD1MXpsFygtrw%3D10.1203/PDR.0b013e3181b24e94Pediatr Res. 2009; 66: 329-335Google Scholar,8.Kishnani P.S. Nicolino M. Voit T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.1:CAS:528:DC%2BD28XntFSns7c%3D10.1016/j.jpeds.2006.02.035J Pediatr. 2006; 149: 89-97Google Scholar In fact, dosing for acid alpha glucosidase is now clinically indicated at essentially an equivalent dosing for all Pompe patients, albeit now being given as a total dose of 20-mg/kg-every-other-week infusion, to reduce the need for frequent intravenous infusions.9.Myozyme. [Package insert]. Genzyme Corporation: Cambridge (MA), 2006.Google Scholar The problems of lack of sustained improvement in motor status in CRIM-negative patients with high-titer antibody have also been verified, indeed new clinical trials attempting to address this concern are ongoing.5.Kishnani P.S. Goldenberg P.C. DeArmey S.L. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.1:CAS:528:DC%2BD1MXhsFGgtb7I10.1016/j.ymgme.2009.08.003Mol Genet Metab. 2010; 99: 26-33Google Scholar,6.Banugaria S.G. Prater S.N. Ng Y.K. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.1:CAS:528:DC%2BC3MXpvVCjurk%3D10.1097/GIM.0b013e3182174703Genet Med. 2011; 13: 729-736Google ScholarDr Reuser is correct in noting that in our original report, we had not disclosed that in latter portions of the first clinical trial for patients 1 and 2 (who had declining AIMS scores and increasing antibody titers), that we attempted to treat these patients with increased doses of the enzyme, as well as various immunomodulatory therapies, in an effort to save these children from continuing their clinical decline. These attempts were ongoing during submission and review of our original manuscript, and were well beyond the scope of that manuscript, requiring further more detailed review and reporting as noted in subsequent publications10.Hunley T.E. Corzo D. Dudek M. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.10.1542/peds.2003-0988-LPediatrics. 2004; 114: e532-e535Google Scholar,11.Banugaria S.G. Patel T.T. Mackey J. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.1:CAS:528:DC%2BC38XjtVOju74%3D10.1016/j.ymgme.2012.01.019Mol Genet Metab. 2012; 105: 677-680Google Scholar as he has indicated. It is, however, clear that these patients had clinical improvement at the 5 mg/kg twice weekly dose before the development of high and sustained antibody titers, time points we focused upon in that manuscript. Thus the conclusions of this dosing regimen (cumulative dose of 20 mg/kg every 2 weeks) still holds true in current clinical practice.In addition, we agree with Dr Reuser that there may be confusion regarding the sentence, “Three patients with infantile Pompe disease have been receiving twice-weekly intravenous infusions of rhGAA for 14 to 17 months,” which we feel has been addressed in the corrigendum to our article (see Corrigendum in this issue), which includes the following information:Three patients with infantile Pompe disease have been receiving at least twice-weekly intravenous infusions of rhGAA for 14–17 months. Patient 1 received 5 mg/kg twice weekly for the first 20 weeks; patient 2 received 5 mg/kg twice weekly for the first 15 weeks; and patient 3 continued to receive the 5-mg/kg-twice-weekly dosing throughout the study. However, after these time points, and because of high antibodies, patients 1 and 2 underwent a series of attempts to induce tolerance to the rhGAA with immunomodulatory therapy and/or increased dosing of the acid alpha glucosidase, attempts that have been subsequently fully described.DisclosureA.A. is on the speakers bureau for Genzyme Corporation; P.S.K. has received research/grant support and honoraria from Genzyme Corporation. P.S.K. is a member of the Pompe and Gaucher Disease Registry Advisory Board for Genzyme Corporation. Y.T.C. has received honoraria from Genzyme Corporation. Alglucosidase alfa rhGAA, in the form of Genzyme’s product alglucosidase alfa, (Myozyme/Lumizyme) has been approved by the US Food and Drug Administration and the European Union as therapy for Pompe disease. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the university’s policy of inventions, patents, and technology transfer. This potential conflict for Duke University has been resolved through monetization. To the Editor: We read with interest the letter by Dr Reuser titled “Inconsistent Reporting About Dosing, Dosing Regimen, and Immunomodulation Therapy in Pompe Disease.”1.Reuser AJJ. Inconsistent reporting about dosing, dosing regimen, and immunomodulation therapy in Pompe disease. Genet Med 2012; doi:10.1038/gim.2012.80.Google Scholar In our 2001 article, “Recombinant Human Acid α-Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of a Phase I/II Clinical Trial,”2.Amalfitano A. Bengur A.R. Morse R.P. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.1:CAS:528:DC%2BD3MXislagu7g%3D1128622911286229Genet Med. 2001; 3: 132-138Google Scholar we had reported the initial use of recombinant human acid α-glucosidase (rhGAA) in three infantile patients with Pompe disease. This was a clinical study where important conclusions were drawn. At that time, we had hypothesized that the lack of sustained efficacy of rhGAA in terms of muscle strength in patients 1 and 2 after 3 to 4 months of the initiation of the therapy was likely due to onset of antibodies against rhGAA in these cross-reactive immunologic material–negative patients, in contrast to the lack of an antibody response noted in the cross-reactive immunologic material–positive patient 3. As several subsequent trials have borne out, the observations and conclusions drawn have been repeated and confirmed, both in regard to the impact that cross-reactive immunologic material–positive status with low antibody titers has on potential for significant cardiac improvement and improvement in motor strength.3.Nicolino M. Byrne B. Wraith J.E. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.1:CAS:528:DC%2BD1MXjt1Sruro%3D10.1097/GIM.0b013e31819d0996Genet Med. 2009; 11: 210-219Google Scholar,4.Kishnani P.S. Corzo D. Nicolino M. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.1:CAS:528:DC%2BD2sXosFSg10.1212/01.wnl.0000251268.41188.04Neurology. 2007; 68: 99-109Google Scholar,5.Kishnani P.S. Goldenberg P.C. DeArmey S.L. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.1:CAS:528:DC%2BD1MXhsFGgtb7I10.1016/j.ymgme.2009.08.003Mol Genet Metab. 2010; 99: 26-33Google Scholar,6.Banugaria S.G. Prater S.N. Ng Y.K. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.1:CAS:528:DC%2BC3MXpvVCjurk%3D10.1097/GIM.0b013e3182174703Genet Med. 2011; 13: 729-736Google Scholar,7.Kishnani P.S. Corzo D. Leslie N.D. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.1:CAS:528:DC%2BD1MXpsFygtrw%3D10.1203/PDR.0b013e3181b24e94Pediatr Res. 2009; 66: 329-335Google Scholar,8.Kishnani P.S. Nicolino M. Voit T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.1:CAS:528:DC%2BD28XntFSns7c%3D10.1016/j.jpeds.2006.02.035J Pediatr. 2006; 149: 89-97Google Scholar In fact, dosing for acid alpha glucosidase is now clinically indicated at essentially an equivalent dosing for all Pompe patients, albeit now being given as a total dose of 20-mg/kg-every-other-week infusion, to reduce the need for frequent intravenous infusions.9.Myozyme. [Package insert]. Genzyme Corporation: Cambridge (MA), 2006.Google Scholar The problems of lack of sustained improvement in motor status in CRIM-negative patients with high-titer antibody have also been verified, indeed new clinical trials attempting to address this concern are ongoing.5.Kishnani P.S. Goldenberg P.C. DeArmey S.L. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.1:CAS:528:DC%2BD1MXhsFGgtb7I10.1016/j.ymgme.2009.08.003Mol Genet Metab. 2010; 99: 26-33Google Scholar,6.Banugaria S.G. Prater S.N. Ng Y.K. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.1:CAS:528:DC%2BC3MXpvVCjurk%3D10.1097/GIM.0b013e3182174703Genet Med. 2011; 13: 729-736Google Scholar Dr Reuser is correct in noting that in our original report, we had not disclosed that in latter portions of the first clinical trial for patients 1 and 2 (who had declining AIMS scores and increasing antibody titers), that we attempted to treat these patients with increased doses of the enzyme, as well as various immunomodulatory therapies, in an effort to save these children from continuing their clinical decline. These attempts were ongoing during submission and review of our original manuscript, and were well beyond the scope of that manuscript, requiring further more detailed review and reporting as noted in subsequent publications10.Hunley T.E. Corzo D. Dudek M. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.10.1542/peds.2003-0988-LPediatrics. 2004; 114: e532-e535Google Scholar,11.Banugaria S.G. Patel T.T. Mackey J. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.1:CAS:528:DC%2BC38XjtVOju74%3D10.1016/j.ymgme.2012.01.019Mol Genet Metab. 2012; 105: 677-680Google Scholar as he has indicated. It is, however, clear that these patients had clinical improvement at the 5 mg/kg twice weekly dose before the development of high and sustained antibody titers, time points we focused upon in that manuscript. Thus the conclusions of this dosing regimen (cumulative dose of 20 mg/kg every 2 weeks) still holds true in current clinical practice. In addition, we agree with Dr Reuser that there may be confusion regarding the sentence, “Three patients with infantile Pompe disease have been receiving twice-weekly intravenous infusions of rhGAA for 14 to 17 months,” which we feel has been addressed in the corrigendum to our article (see Corrigendum in this issue), which includes the following information: Three patients with infantile Pompe disease have been receiving at least twice-weekly intravenous infusions of rhGAA for 14–17 months. Patient 1 received 5 mg/kg twice weekly for the first 20 weeks; patient 2 received 5 mg/kg twice weekly for the first 15 weeks; and patient 3 continued to receive the 5-mg/kg-twice-weekly dosing throughout the study. However, after these time points, and because of high antibodies, patients 1 and 2 underwent a series of attempts to induce tolerance to the rhGAA with immunomodulatory therapy and/or increased dosing of the acid alpha glucosidase, attempts that have been subsequently fully described. DisclosureA.A. is on the speakers bureau for Genzyme Corporation; P.S.K. has received research/grant support and honoraria from Genzyme Corporation. P.S.K. is a member of the Pompe and Gaucher Disease Registry Advisory Board for Genzyme Corporation. Y.T.C. has received honoraria from Genzyme Corporation. Alglucosidase alfa rhGAA, in the form of Genzyme’s product alglucosidase alfa, (Myozyme/Lumizyme) has been approved by the US Food and Drug Administration and the European Union as therapy for Pompe disease. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the university’s policy of inventions, patents, and technology transfer. This potential conflict for Duke University has been resolved through monetization. A.A. is on the speakers bureau for Genzyme Corporation; P.S.K. has received research/grant support and honoraria from Genzyme Corporation. P.S.K. is a member of the Pompe and Gaucher Disease Registry Advisory Board for Genzyme Corporation. Y.T.C. has received honoraria from Genzyme Corporation. Alglucosidase alfa rhGAA, in the form of Genzyme’s product alglucosidase alfa, (Myozyme/Lumizyme) has been approved by the US Food and Drug Administration and the European Union as therapy for Pompe disease. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the university’s policy of inventions, patents, and technology transfer. This potential conflict for Duke University has been resolved through monetization." @default.
• W2016040578 created "2016-06-24" @default.
• W2016040578 creator A5003784869 @default.
• W2016040578 creator A5059948406 @default.
• W2016040578 date "2012-09-01" @default.
• W2016040578 modified "2023-09-25" @default.
• W2016040578 title "Response to Reuser" @default.
• W2016040578 cites W1523209662 @default.
• W2016040578 cites W1790440725 @default.
• W2016040578 cites W1965518007 @default.
• W2016040578 cites W1972094493 @default.
• W2016040578 cites W1989909815 @default.
• W2016040578 cites W2000846576 @default.
• W2016040578 cites W2007517041 @default.
• W2016040578 cites W2029671550 @default.
• W2016040578 cites W2042293234 @default.
• W2016040578 cites W2043385706 @default.
• W2016040578 cites W2074252634 @default.
• W2016040578 cites W2080902960 @default.
• W2016040578 cites W2101099004 @default.
• W2016040578 cites W2112904522 @default.
• W2016040578 cites W2133444266 @default.
• W2016040578 cites W2134197747 @default.
• W2016040578 cites W2146877343 @default.
• W2016040578 cites W2150885355 @default.
• W2016040578 cites W2155965977 @default.
• W2016040578 cites W2165008949 @default.
• W2016040578 cites W2473786944 @default.
• W2016040578 cites W2607031541 @default.
• W2016040578 cites W4237772203 @default.
• W2016040578 doi "https://doi.org/10.1038/gim.2012.81" @default.
• W2016040578 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3908501" @default.
• W2016040578 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22878505" @default.
• W2016040578 hasPublicationYear "2012" @default.
• W2016040578 type Work @default.
• W2016040578 sameAs 2016040578 @default.
• W2016040578 citedByCount "19" @default.
• W2016040578 countsByYear W20160405782014 @default.
• W2016040578 countsByYear W20160405782015 @default.
• W2016040578 countsByYear W20160405782016 @default.
• W2016040578 countsByYear W20160405782017 @default.
• W2016040578 countsByYear W20160405782018 @default.
• W2016040578 countsByYear W20160405782019 @default.
• W2016040578 countsByYear W20160405782021 @default.
• W2016040578 countsByYear W20160405782022 @default.
• W2016040578 crossrefType "journal-article" @default.
• W2016040578 hasAuthorship W2016040578A5003784869 @default.
• W2016040578 hasAuthorship W2016040578A5059948406 @default.
• W2016040578 hasBestOaLocation W20160405781 @default.
• W2016040578 hasConcept C71924100 @default.
• W2016040578 hasConceptScore W2016040578C71924100 @default.
• W2016040578 hasIssue "9" @default.
• W2016040578 hasLocation W20160405781 @default.
• W2016040578 hasLocation W20160405782 @default.
• W2016040578 hasOpenAccess W2016040578 @default.
• W2016040578 hasPrimaryLocation W20160405781 @default.
• W2016040578 hasRelatedWork W1506200166 @default.
• W2016040578 hasRelatedWork W1995515455 @default.
• W2016040578 hasRelatedWork W2048182022 @default.
• W2016040578 hasRelatedWork W2080531066 @default.
• W2016040578 hasRelatedWork W2604872355 @default.
• W2016040578 hasRelatedWork W2748952813 @default.
• W2016040578 hasRelatedWork W2899084033 @default.
• W2016040578 hasRelatedWork W3031052312 @default.
• W2016040578 hasRelatedWork W3032375762 @default.
• W2016040578 hasRelatedWork W3108674512 @default.
• W2016040578 hasVolume "14" @default.
• W2016040578 isParatext "false" @default.
• W2016040578 isRetracted "false" @default.
• W2016040578 magId "2016040578" @default.
• W2016040578 workType "article" @default.